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BACKGROUND: Leptin has physiological roles in multiple systems, and has possible effects on several
carcinogenesis steps. The aim of this study was to investigate the leptin levels in thyroid papillary carci-
noma (TPC) patients.
METHODS: Forty-three female TPC patients and 30 healthy female control subjects were recruited 
for the study. TPC was diagnosed by fine needle aspiration biopsy. TPC patients had a bilateral total 
thyroidectomy operation and their leptin levels were measured before and 20 days after the operation.
RESULTS: Serum leptin levels of TPC patients were higher than in control group subjects
(21.15 ± 14.12 ng/mL vs. 9.89 ± 0.21 ng/mL, p < 0.05). The leptin levels decreased after total thyroidectomy
(13.92 ± 10.55 ng/mL) compared to prethyroidectomy levels (22.94 ± 14.67 ng/mL) in 34 patients who
came to the follow-up visit (p < 0.05). However, the decreased post-thyroidectomy levels of leptin were still
statistically significantly higher than the control group levels. Multivariate regression analysis showed
that the leptin levels in TPC patients were not related to age, menopausal status or pathologic occult status
but were directly related to the cancer group.
CONCLUSION: Leptin levels were elevated in thyroid cancer, decreased after total thyroidectomy, and
might be associated with thyroid papillary carcinogenesis. [Asian J Surg 2009;32(4):216–23]
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Introduction
Leptin, which increases parallel to body mass index (BMI),
is becoming attractive to researchers with the increasing
prevalence of overweight and obesity in the United States.1
In 1994, Zhang and colleagues reported the cloning of the
obese (ob) gene, responsible for the typical phenotype of
obesity, diabetes and insulin resistance in ob/ob mice and
human homologue gene, which was 84% identical with
the mouse protein.2 Leptin receptors were cloned and
identified in the choroid plexus and hypothalamus, a
region known to be involved in the regulation of appetite,
food intake and body weight.3,4 Formerly, it was thought
that leptin had a role in regulating body weight solely by
regulating body fat stores, but leptin is not only impor-
tant in the regulation of food intake and energy balance,
it also has a function as a metabolic and neuroendocrine
hormone. Leptin has roles in glucose metabolism, normal
sexual maturation and reproduction, and effects on 
the hypothalamic-pituitary-adrenal, thyroid and growth
hormone axes, haematopoiesis and the immune system.5
Leptin may modulate different mechanisms in several 
systems such as activating or inhibiting the ongoing steps
of the disorders, and the knowledge of the relationship
between obesity and certain cancer types makes leptin 
a research target for other types of cancers.
Address correspondence and reprint requests to Dr Melih Akinci, 44 Cadde 457, Sokak Lale Apt. No. 4/14, 06520
Cukurambar, Ankara, Turkey.
E-mail: melihakinci@yahoo.com ● Date of acceptance: 5 September 2008
■ LEPTIN IN THYROID CANCER ■
ASIAN JOURNAL OF SURGERY VOL 32 • NO 4 • OCTOBER 2009 217
With respect to its diverse functions in immunity, 
leptin may have a major role in oxidation, which is an
important risk factor in carcinogenesis. Indeed, obesity
has long been recognised to be a risk factor for tumorige-
nesis, and accumulating evidence suggests that leptin is a
potential link between obesity and cancer development.
While leptin serves as a pivotal factor in immune surveil-
lance, it has been shown to act as a mitogenic agent to
promote the proliferation and invasiveness of certain can-
cer cells.6 Leptin, as a product of adipose tissue and a neu-
roendocrine hormone, with its effects on immunologic
events as well as body energy regulation, has physiologi-
cal roles in multiple systems. It has possible effects on 
several carcinogenesis steps and roles in renal cell carci-
noma, melanoma, breast, colon, prostate, lung, endome-
trial and ovarian cancer.7–15
Leptin as a cytokine has never been analysed in thyroid
cancer patients. The aims of this study were to investigate
the leptin levels in thyroid papillary carcinoma (TPC)
patients before and after total thyroidectomy, and to
compare the leptin levels in TPC patients with healthy
controls.
Patients and Methods
The study was approved by the hospital’s ethics commit-
tee. All the patients and the volunteers involved in the
study gave informed consent.
Trained physicians recruited subjects by convenience
sampling at the General Surgery Clinic of Ankara Oncology
Hospital, Turkey. Forty-three TPC patients and 30 con-
trol subjects were included in this study. The patients
were females presenting with papillary carcinoma of the
thyroid. No patient had clinically palpable lymph nodes
or lymph nodes detected by ultrasonography. All the
patients underwent total thyroidectomy without lymph
node dissection and came to a follow-up visit on the 20th
postoperative day. None of the patients received thyroid
hormone postoperatively in preparation for radioactive
iodine therapy. The patients received radioactive iodine
administration 5–6 weeks after thyroidectomy. Blood
samples for leptin level measurements were taken from the
patients preoperatively and on the 20th postoperative day,
and once from the control subjects. Patients and control
groups were euthyroid with normal thyroid function tests
and had normal levels of total cholesterol and triglycerides.
Patients and controls with diabetes mellitus, hypertension
and those on hormonal therapy such as oral contracep-
tives, thyroxin derivatives, estrogen replacement therapy
and also medications for chronic diseases were excluded.
The controls were sex-matched healthy volunteers.
Patients with tumour size less than 10 mm without
capsule invasion and angioinvasion were classified as hav-
ing occult carcinoma,16 whereas larger tumours were clas-
sified as nonoccult carcinoma for subgroup analysis. As
leptin is a product of adipose tissue and increases in par-
allel with obesity, subgroups related to BMI for patients
and controls were also analysed. BMI subgroups were
defined as underweight, normal, overweight, and obese,
i.e. < 18.5 kg/m2, 18.5–25 kg/m2, 25–30 kg/m2, and > 30 kg/
m2, respectively.17 Underweight and normal subjects were
grouped together; therefore, three BMI subgroups for
both patients and controls were analysed.
Blood samples were kept at −40°C until analysis. All
samples from each patient were run in the same assay.
Serum thyroid hormones were measured by radioimmu-
noassay kits (Tosoh AIA-600 autoanalyzer; Tosoh Corp.,
Tokyo, Japan). Total cholesterol and triglycerides were
measured by Beckman Coulter DXC 800 autoanalyzer
(Beckman Coulter Inc., Fullerton, CA, USA). Leptin levels
were determined by human serum ELISA (TiterZyme®
Enzyme Immunometric Assay Kit; Assay Designs Inc.,
Ann Arbor, MI, USA).
All statistical analyses were performed using SPSS 11.5
(SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov
test was used to test the normal distribution of the data.
Student’s t-test was used to compare the numeric data
between the groups. The paired t-test was used to analyse
the variables before and after the operation. Chi-square
test was used to analyse categorical variables. Multivariate
regression analysis was performed to analyse the effect of
the independent variables (group, age, menopausal sta-
tus) on the dependent variable (leptin levels). Two-tailed
probability (p) values were calculated throughout, and
statistical significance was defined as p < 0.05.
Results
The levels of thyroid hormones, total cholesterol, tri-
glycerides and glucose were within normal limits in all 
subjects. Sex (all of the subjects were female), weight,
height and BMI were not significantly different between
the TPC patients and control group subjects (Table 1).
TPC patients were younger than the control subjects
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(p < 0.05). In multivariate regression analysis with age and
group as the independent variables, and preoperative lep-
tin level as the dependent variable, age was not statis-
tically significant (p = 0.27) but the group variable was
(p < 0.001).
Forty-three female TPC patients and 30 healthy control
women had serum leptin levels of 21.15 ± 14.12 ng/mL
and 9.89 ± 0.21 ng/mL, respectively. Leptin levels of TPC
patients were significantly higher than those in control
group subjects (p < 0.05). TPC patients underwent bi-
lateral total thyroidectomy and their leptin levels were
remeasured 20 days after the operation. The mean leptin
level of 34 TPC patients who had total thyroidectomy and
came to the follow-up visit for blood sampling was
13.92 ± 10.55 ng/mL. The mean prethyroidectomy leptin
level of these 34 patients was 22.94 ± 14.67 ng/mL, and if
this is compared with the post-thyroidectomy leptin level,
a significant decrease was observed (p < 0.05) (Table 2).
However, the decreased post-thyroidectomy leptin level
was still statistically significantly higher than the control
group’s leptin level (Table 2).
Leptin is secreted from adipose tissue and its level
increases with total adipose tissue, correlating with BMI.
Mean BMI of TPC patients and the control group was
26.3±4.9 kg/m2 and 26.2±3.8 kg/m2, respectively (p >0.05).
As BMI affects leptin levels directly, an analysis of BMI
subgroups was also performed (Table 3) and showed that
the two groups were similar regarding the number of
patients within each BMI subgroup (p > 0.05). In TPC
patients, the preoperative and postoperative leptin levels
in BMI subgroups are detailed in Table 4. The leptin lev-
els decreased postoperatively in all BMI subgroups in TPC
patients (p < 0.05).
As a neuroendocrine hormone, leptin may be affected
by menopausal status due to associated hormonal change.
Subgroups of menopausal status were analysed for both
groups. The control group were older and had a higher
percentage of postmenopausal subjects than the TPC
group (p < 0.05) (Table 3).
Statistical analysis of premenopausal and postmeno-
pausal TPC and control subjects’ leptin levels showed no
difference (p > 0.05) (Table 5). Multivariate regression
analysis showed that leptin levels were related to the
group variable (p < 0.001) but not to menopausal status
(p = 0.193).
The decrease in the leptin level in TPC patients after
total thyroidectomy was not related to menopausal status.
Preoperatively, the mean ± SD serum leptin level was
18.89 ± 11.01 ng/mL in 30 premenopausal patients and
26.36 ± 19.03 ng/mL in 13 postmenopausal patients. The
Table 1. Demographic characteristics of thyroid papillary carcinoma patients and control subjects
Group n Mean Standard deviation
Age Thyroid cancer 43 42.8* ± 13.2
Control 30 54.6* ± 8.9
Height (cm) Thyroid cancer 43 161.0 ± 6.8
Control 30 159.8 ± 9.2
Weight (kg) Thyroid cancer 43 68.1 ± 13.2
Control 30 67.0 ± 12.5
BMI (kg/m2) Thyroid cancer 43 26.3 ± 4.9
Control 30 26.2 ± 3.8
*p< 0.05.
Table 2. Preoperative and postoperative leptin levels in thyroid papillary carcinoma (TPC) patients and control subjects
n Mean Standard deviation
TPC, prethyroidectomy, leptin (ng/mL) 34 22.94*/† ± 14.67
Control, leptin (ng/mL) 30 9.89*/‡ ± 0.21
TPC, post-thyroidectomy, leptin (ng/mL) 34 13.92*/†/‡ ± 10.55
*p< 0.05; †p< 0.05; ‡p< 0.05.
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serum leptin level in the TPC group on postoperative day
20 did not significantly differ between premenopausal
(12.81 ± 8 ng/mL, n = 22) and postmenopausal patients
(15.95 ± 14.1 ng/mL, n = 12) (p > 0.05).
The postoperative pathological examination of 43 TPC
patients showed that seven specimens had occult and 36
had nonoccult thyroid cancer. The comparison of leptin
levels of these two groups showed no difference (p > 0.05).
On postoperative day 20, the mean ± SD leptin levels of
six occult (11.93 ± 7.89 ng/mL) and 28 nonoccult
(14.34 ± 11.1 ng/mL) cancer patients showed no differ-
ence when compared with the preoperative leptin levels 
in seven occult (17.82 ± 14.85 ng/mL) and 36 nonoccult
(21.79 ± 14.10 ng/mL) patients, respectively.
Prethyroidectomy leptin levels of both occult and
nonoccult TPC patients were higher than those in the
control group (p < 0.05); after total thyroidectomy, the
decreases in both groups were statistically significant
(p < 0.05) (Table 6).
Discussion
In this study, we found that the serum leptin levels of TPC
patients were higher than those in control group subjects.
The leptin levels decreased after total thyroidectomy com-
pared to prethyroidectomy levels. However, the decreased
post-thyroidectomy leptin levels were still statistically sig-
nificantly higher than the control group levels. The leptin
Table 4. Mean ± standard deviation leptin levels (ng/mL) in body mass index (BMI) subgroups of thyroid papillary carcinoma patients
BMI subgroup n Preoperative Postoperative p
Underweight/normal (< 25 kg/m2) 13 18.4 ± 12.5 11.4 ± 10 < 0.001
Overweight (25–30 kg/m2) 12 22.9 ± 10.2 13.6 ± 7.5 < 0.001
Obese (> 30 kg/m2) 9 29.5 ± 20.7 17.9 ± 14.3 0.002
p between subgroups 0.225 0.365
Table 5. Leptin levels of premenopausal and postmenopausal thyroid papillary carcinoma (TPC) and control subjects
Group Menopausal status n Mean leptin (ng/mL) Standard deviation
TPC Premenopausal 30 18.89* ± 11.01
Postmenopausal 13 26.36* ± 19.03
TPC, total 43 21.15 ± 14.11
Control Premenopausal 8 9.92† ± 0.08
Postmenopausal 22 9.88† ± 0.24
Control, total 30 9.89 ± 0.21
Total 73 16.52 ± 12.14
*/†p> 0.05.
Table 3. Subgroup analysis of thyroid papillary carcinoma (TPC) and control groups*
Group
TPC Control
BMI
Underweight/normal (< 25 kg/m2) 18 (42) 11 (37)
Overweight (25–30 kg/m2) 16 (37) 16 (53)
Obese (> 30 kg/m2) 9 (21) 3 (10)
Menopausal status†
Premenopausal 30 (70)† 8 (27)
Postmenopausal 13 (30) 22 (73)
*Data presented as number of patients (%); †p< 0.05.
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levels in TPC patients were not related to age, menopausal
status or pathologic occult status, but were directly
related to the cancer group.
First of all, the association between leptin and thyroid
hormones should be explored. Leptin and thyroid hor-
mones have similar effects on thermogenesis and energy
metabolism; the possibility has been raised that they 
both exert their effects through the same pathways, i.e.
regulation of sympathetic nervous system activity, mainly
adrenergic upregulation.5 At the level of the pituitary gland,
leptin was recently shown to be expressed by thyroid stim-
ulating hormone (TSH) cells too.18 Prolonged fasting is
associated with a fall in leptin levels and in thyroid hor-
mones. Leptin administration to fasted mice decreased
the fall in thyroxine (T4)/TSH induced by fasting,19
restored the reduced plasma levels of total and free tri-
iodothyronine (T3) and T4 to normal levels, and sup-
pressed proTRH mRNA in paraventricular neurons.20
However, thyroid hormones have an inhibitory effect on
leptin expression or secretion since thyroid hormones
have a permissive role on the effects of catecholamines on
beta-adrenergic receptors, and since stimulation of these
receptors suppresses leptin expression.21 Leptin was ele-
vated in thyroidectomised rats compared with controls,
and infusion of T3 or T4 to these rats decreased leptin 
levels.22 Administration of T3 to hypothyroid rats also
decreased leptin mRNA expression in adipose tissue and
circulating leptin levels.21 Possible effects of low versus
high thyroid hormone levels on leptin levels were studied
in hypothyroid and hyperthyroid patients, with conflicting
results.5 Although thyroid dysfunction seems not to have
a significant effect on leptin levels in man, we included
euthyroid subjects in our study for both TPC patients and
control subjects for standardisation.
One of the main questions is what the leptin level 
is in other types of thyroid diseases, such as benign 
multinodular goitre or follicular adenomas that undergo 
surgical treatment. Serum leptin levels were reported 
to be unchanged in Basedow-Graves and multinodular
goitre patients.23 However, serum leptin levels were found
to be high in postpartum thyroiditis patients.24 The asso-
ciation of increased leptin levels in thyroiditis and in can-
cer patients could be explained by the fact that the
immune system is one of the targets of leptin activity. Our
study included euthyroid patients who underwent total 
thyroidectomy after fine needle aspiration had showed
malignant features. It would have been interesting to have
a control group of patients with a benign disease such as
goitre in our study, but total thyroidectomy is rarely per-
formed for benign disease and euthyroid patients. Although
there have been conflicting reports on the effects of hypo-
thyroidism and hyperthyroidism on leptin levels and on
the interaction between leptin and the pituitary-thyroid
axis in humans,25 it has been documented that plasma
leptin levels are elevated in hypothyroid patients and
decreased in hyperthyroid patients.21,22,25–29 Contrastingly,
other authors have not reported any significant changes
in leptin levels in hypo- or hyperthyroidism.30–32 Elevation
of or no significant change in leptin levels after total thy-
roidectomy in hypothyroidism is an acceptable condition
but the decreased levels as seen in our study are unex-
pected, and therefore support the idea of a relationship
between leptin and thyroid cancer. It would be interesting
to follow leptin levels serially in these postoperative
patients until the point when the patients are on chronic
thyroid hormone replacement therapy.
The synthesis of leptin in adipocytes is influenced 
by different humoral factors, most notably insulin,33,34
tumour necrosis factor-alpha (TNF-α),2 glucocorti-
coids,35,36 reproductive hormones,37 and prostaglan-
dins.38 Importantly, many of these factors have been
shown to be associated with neoplastic processes39 and
Table 6. Leptin levels of occult and nonoccult thyroid papillary carcinoma (TPC) patients compared with pre- and post-thyroidectomy
status
Group n Mean leptin (ng/mL) Standard deviation
Control 30 9.89*/† ± 0.21
Occult Prethyroidectomy TPC 7 17.82* ± 14.85
Post-thyroidectomy TPC 6 11.93† ± 7.89
Nonoccult Prethyroidectomy TPC 36 21.79* ± 14.10
Post-thyroidectomy TPC 28 14.34† ± 11.11
*/†p< 0.05.
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support our findings in this study. Leptin expression can
be induced under hypoxic conditions, which often occur
in solid tumours.39,40 Hypoxia and chemical inducers of
cellular hypoxia are able to activate the leptin gene pro-
moter through the hypoxia-induced factor-1 in human
adipocytes and fibroblasts.40,41 These data suggest that
leptin may play a role in vascular remodelling.42 Indeed,
leptin has been shown to regulate neoangiogenesis by
itself and in concert with vascular endothelial growth 
factor and fibroblast growth factor.43,44 In addition to its
proangiogenic function, leptin can enhance endothelial
cell growth43,44 and suppress apoptosis through a Bcl-2-
dependent mechanism.45 The role of leptin in neovascu-
larisation is supported additionally by the observation
that the hormone can increase the levels and activity of
enzymes involved in angiogenesis, for example, matrix
metalloproteinases 2 and 9.46,47 In addition to its involve-
ment in endothelial cell function, leptin has been shown
to act as a mitogen, transforming factor, or migration 
factor for many different cell types, including smooth
muscle cells,48 normal and neoplastic colon cells,49,50 and
normal and malignant mammary epithelial cells.51,52
Higher levels of leptin in the TPC group than in the
control group and the significant decrease after total thy-
roidectomy in the same subjects make leptin a possible
etiologic factor in thyroid carcinogenesis, at least in one
step. However, the decreased post-thyroidectomy levels of
leptin were still significantly higher than the control
group levels of leptin, which may be related to hypothy-
roidism during the postoperative period for TSH stimu-
lation. Leptin levels have been shown to increase with
hypothyroidism.53
Leptin is synthesised and secreted mainly by fat cells,
and its plasma levels in humans are strongly correlated
with BMI.54 Thus, we analysed the BMI subgroups in
both TPC and control groups and found no significant
differences in these BMI subgroups. The leptin levels
decreased postoperatively in all BMI subgroups in TPC
patients.
In this study, all the patients and healthy control sub-
jects were female because it is known that an increase in
testosterone is associated with a decrease in the plasma
concentration of leptin.55 All the patients had the diagno-
sis of TPC for standardisation. Although leptin levels in
male thyroid carcinoma subjects and in benign thyroid
disorders remain unknown with this series, this is a pio-
neer study and the authors primarily aimed to compare
the leptin levels in thyroid carcinoma in a homogeneous
group. Another study including benign thyroid disorder
subgroups would be interesting in order to see the rela-
tionship between leptin and malignancy.
In spite of the fact that we still do not know about
benign thyroid disorders, leptin levels were elevated in thy-
roid cancer and they decreased after total thyroidectomy.
Therefore, this pioneer study suggests a possible associa-
tion between TPC and leptin.
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